With the fast-growing evidence and as the use of SGLT-2 inhibitors becomes more popular in patients with or without diabetes, it is crucial to understand the benefits of these medications and to communicate them to the patient and health care providers [41,42]. The gene discussed is SLC5A2; the disease is diabetes mellitus.